FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf
This article was originally published in The Pink Sheet Daily
Executive Summary
In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.